Would you use alpelisib in patients with biopsy proven hormone negative metastatic breast cancer with a PIK3CA alteration?

The rationale for using PIK3CA inhibitors is to overcome endocrine resistance by combining this treatment with endocrine therapy in ER positive breast cancer. There is no particular logic or data to support using single agent PIK3CA inhibitors in mutation carriers to my knowledge, nor would it make ...

Additionally, to reinforce what Dr. @Dr. First Last said, we have data from SABCS20 showing that AKT inhibitor: Ipatasertib (added to paclitaxel) did NOT significantly improve PFS in advanced TNBC with PIK3CA/AKT1 alteration. Therefore, unlikely that Alpelisib would work in HR negative tumors.